|
|
 |
|
Viewing report
|
|
|
|
Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Jan 2012, Pages: 147
Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006–2010. During 2010–2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market.
The cancer vaccines therapeutic market is expected to show high growth in the forecast period to 2018 due to the expected launch of first-in-class therapeutic cancer vaccines. Presently, there is only one therapeutic cancer vaccine, Provenge, which is a dendritic cell vaccine for advanced prostate cancer patients. Provenge received approval in April 2010 and is presently available only in the US. Dendreon is expecting to file Provenge in Europe in early 2012 and is expected to be launched on the market by mid-2013, which will help drive the therapeutic cancer vaccine market during the forecast period. The expected launch of first-in-class vaccines for different types of cancer during the forecast period to 2018 is expected to drive the cancer vaccines therapeutics market.
These drugs include:
Allovectin-7 for Melanoma
BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma in Europe and the US,
Oncovex for melanoma
Stimuvax (BLP25 liposome vaccine) for unresectable stage III NSCLC (non-small cell lung cancer).
Due to the launch of first-in-class vaccines during the forecast period the therapeutic cancer vaccines market is expected to show high growth.
Scope
The report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine, heated-killed yeast-based vaccine etc.
- Analysis of the current and future competition in the seven key countries cancer vaccines market. Key market players covered are Merck, NovaRx Corporation, NewLink Genetics Corporation, Bavarian Nordic, immatics biotechnologies GmbH, Oxford BioMedica, Biovex, Vaccinogen, Biovest International, Vaccinogen and GlaxoSmithKline.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the cancer vaccines market.
- Analysis of key recent licensing and partnership agreements in cancer vaccines market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global cancer vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global cancer vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global cancer vaccines market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
